Two studies using panels of SMARCA4- and/or SMARCA2- mutated cell lines derived from small cell carcinoma of the ovary-hypercalcemic type (SCCOHT), lung, gastric and bladder cancer have shown that the efficacy of the EZH inhibitor tazemetostat was far less when only one of the two components was affected [60,61], similar to cell line TCS627. This evidence concerns the gene SMARCA4 and ovarian small cell carcinoma.